MBL (Medical & Biological Laboratories Co., Ltd.)

MBL began its history as the first Japanese company specializing in the production and supply of antibodies and celebrated its 50th anniversary in August 2019. In the 1970s, for the first time in Japan, we began to develop autoimmune disease reagents and succeeded in launching a series of autoantibody reagents. Currently, these reagent products are our main-stream business. In the 1980s, we expanded business into the field of laboratory research reagents and launched many original products such as antiserum and monoclonal antibodies, IL-18 products, and MHC tetramers. Starting in the 2000s, we began to promote sales of molecular diagnostic reagents, and this business has grown to become our second largest sector. Then we have begun contract R&D services for developing companion diagnostics from last year. We expanded business operations into China in 2005. Since then, revenue has been steadily increasing not only for laboratory research reagents but also for raw materials and intermediates of diagnostic reagents. China is now one of the most important market for the company. We are committed to providing a range of cutting-edge products and services that will benefit society.

Company’s Keywords:

in vitro diagnostics, companion diagnostics, cancer, autoimmune diseases, covid19, cancer immunity, organoid, nudt15, mhc tetramers, il18, ifa